Nimotuzumab with nab-paclitaxel and gemcitabine for EGFR-positive pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of Nimotuzumab combined with nab-paclitaxel and gemcitabine as postoperative adjuvant therapy for patients with EGFR-positive pancreatic cancer. It is a prospective, open-label, single-arm phase II study focusing on disease-free survival as the primary endpoint. Additional endpoints include distant metastasis-free survival, overall survival, tumor-related markers, and safety assessments. The study aims to provide insights into the effectiveness of this combination therapy in improving patient outcomes after surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Able and willing to provide a written informed consent.
* 2\. Age 18-75 years old, gender unlimited;
* 3\. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;
* 4\. Postoperative pathology suggested R0/R1 resection;
* 5\. EGFR positive (by immunohistochemistry);
* 6\. KRAS gene and CDX-2 protein status must have been determined at baseline (only for post hoc analysis);
* 7\. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10\^9/L; platelets≥80×10\^9/L; hemoglobin≥9.0 g/dL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \> 60 mL/min;
* 8\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
* 9\. Postoperative survival is expected to be ≥3 months;
* 10\. Fertile subjects are willing to take contraceptive measures during the study period.

Exclusion Criteria:

* 1\. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
* 2\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
* 3\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\>160mmHg or DBP\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
* 4\. Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
* 5\. CA199\>180 U/ml within 21d before adjuvant therapy;
* 6\. Known allergy to prescription or any component of the prescription used in this study;
* 7\. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
* 8 .Other reasons that are not suitable to participate in this study according to the researcher\'s judgment.

Where it's running

• Zhejiang Provincial People's Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yiping Mou, Dr
• Email: mouyiping@hmc.edu.cn
• Phone: 0086-057185893643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Chronic Stress and Pancreatic Cancer Outcomes in People with Pancreatic Cancer

  This study tests whether ongoing psychological stress affects how pancreatic cancer behaves and responds to treatment in adults.

  Recruiting Shanghai Zhongshan Hospital · Changsha, Hunan and 2 other locations · NCT07529626

• Neoadjuvant chemoradiotherapy with serplulimab and nimotuzumab for resectable locally advanced esophageal squamous cell carcinoma

  This trial will try adding serplulimab and nimotuzumab to preoperative chemoradiotherapy to see if it improves surgical and pathological outcomes for adults with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07457528

• Postoperative radiotherapy with nimotuzumab followed by bemcentinib for high-risk head and neck cancer patients who can't take cisplatin

  This study will see if adding nimotuzumab during postoperative radiotherapy followed by bemcentinib can help prevent recurrence in high-risk head and neck cancer patients who are unable to receive cisplatin.

  Recruiting Phase 3 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT07445048

• Nimotuzumab plus toripalimab and chemotherapy for locally advanced tonsillar cancer

  This trial will try giving nimotuzumab and toripalimab together with chemotherapy before surgery to see if it increases complete tumor response in people with resectable, locally advanced tonsillar cancer.

  Recruiting Phase 2 Tang-Du Hospital · Shanxi, Province · NCT07353723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.